|AHFS/Drugs.com||International Drug Names|
|By mouth, topical|
|Elimination half-life||~3 h|
|Excretion||50% urine, 36% feces|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||281.234 g·mol−1|
|3D model (JSmol)|
|Melting point||124 to 125 °C (255 to 257 °F) resolidification and remelting at 134°C to 136°C|
|Solubility in water||Practically insoluble in water; soluble in ethanol, chloroform and diethyl ether mg/mL (20 °C)|
Flufenamic acid (FFA) is a member of the anthranilic acid derivatives (or fenamate) class of nonsteroidal anti-inflammatory drugs (NSAIDs).: 718 Like other members of the class, it is a cyclooxygenase (COX) inhibitor, preventing the formation of prostaglandins. FFA is known to bind to and reduce the activity of prostaglandin F synthase and activate TRPC6.
It is not widely used in humans as it has a high rate (30–60%) of gastrointestinal side effects.: 310 It is generally not available in the US. It is available in some Asian and European countries as a generic drug.
Scientists led by Claude Winder from Parke-Davis invented FFA in 1963, along with fellow members of the class, mefenamic acid in 1961 and meclofenamic acid in 1964.: 718
Although flufenamic acid was at one time informally referred to as "Fluffy" (see history cache), this pet name could also refer to flufenoxine.
Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
|acetic acid derivatives|
and related substances
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use.